Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index; 24 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to reduce the risk of adverse cardiovascular events in patients with diabetes. Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes is unknown. METHODS: In a multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or older who had preexisting cardiovascular disease and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 27 or greater but no history of diabetes. Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke in a time-to-first-event analysis. Safety was also assessed. RESULTS: A total of 17,604 patients were enrolled; 8803 were assigned to receive semaglutide and 8801 to receive placebo. The mean (±SD) duration of exposure to semaglutide or placebo was 34.2±13.7 months, and the mean duration of follow-up was 39.8±9.4 months. A primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and in 701 of the 8801 patients (8.0%) in the placebo group (hazard ratio, 0.80; 95% confidence interval, 0.72 to 0.90; P<0.001). Adverse events leading to permanent discontinuation of the trial product occurred in 1461 patients (16.6%) in the semaglutide group and 718 patients (8.2%) in the placebo group (P<0.001). CONCLUSIONS: In patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months. (Funded by Novo Nordisk; SELECT ClinicalTrials.gov number, NCT03574597.).
Overview
CoChat Summary
## TL;DR
In this multicenter randomized trial of adults with preexisting cardiovascular disease, overweight or obesity, and no diabetes, weekly semaglutide 2.4 mg reduced major cardiovascular events versus placebo over a mean 39.8 months. The benefit came with more adverse-event-related discontinuation, especially gastrointestinal events.
## Key findings
- The primary composite cardiovascular end point occurred in 569/8803 (6.5%) semaglutide patients vs 701/8801 (8.0%) placebo patients (hazard ratio 0.80; 95% CI, 0.72 to 0.90; P<0.001).
- Mean body weight change over 104 weeks was -9.39% with semaglutide vs -0.88% with placebo, an estimated treatment difference of -8.51 percentage points (95% CI, -8.75 to -8.27).
- Adverse events leading to permanent discontinuation occurred in 1461 (16.6%) semaglutide patients vs 718 (8.2%) placebo patients (P<0.001); gastrointestinal disorders accounted for 880 (10.0%) vs 172 (2.0%).
- The paper reports fewer serious adverse events with semaglutide: 2941 (33.4%) vs 3204 (36.4%) (P<0.001), while gallbladder-related disorders were slightly higher: 246 (2.8%) vs 203 (2.3%) (P=0.04).
## Methods
- Multicenter, double-blind, randomized, placebo-controlled, event-driven superiority trial at 804 clinical sites in 41 countries.
- Enrolled 17,604 patients aged 45 years or older with BMI ≥27, established cardiovascular disease, and no history of diabetes; randomized 1:1 to weekly subcutaneous semaglutide 2.4 mg or placebo.
- Primary analysis was intention-to-treat time-to-first-event analysis using a Cox proportional hazards model; secondary end points were tested hierarchically.
## Limitations
- The paper states that it included only patients with preexisting cardiovascular disease, so effects on primary prevention in people with overweight/obesity but no prior atherosclerotic disease were not studied.
- The authors note the patient population was not globally representative, with 27.7% women and 3.8% Black persons enrolled.
- Evident from the report: although mean follow-up was 39.8 months, the x-axis in the figure is truncated at 48 months because of limited patients after that time, so very long-term effects are not fully established.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
17 Valid · 0 Not valid · 5 Not checked · 53 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Perivascular and epicardial adipose tissue impose direct adverse effects on the vascular endothelium and myocardium. 30”
What the sources say
- Partly supportedcites [30] 30. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol 2022; 19: 593-606. sourceExperimental — accuracy not yet measured
The Introduction says epicardial adipose tissue (EAT) can harm adjacent myocardium through inflammatory and profibrotic secretions, and the Coronary artery disease section says EAT secretes factors associated with increased endothelial permeability. The paper identifies pericoronary EAT around coronary arteries, but does not establish the claim for perivascular adipose tissue generally. It also describes EAT as protective under normal conditions, so the unqualified assertion of adverse effects overstates the source. These sections have no page numbers in our copy. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide, a long-acting analogue of GLP-1, administered at a dose of 2.4 mg subcutaneously once weekly for 104 weeks, was found to reduce body weight by a mean of 15.2% among patients with overweight or obesity who did not have diabetes. 18”
What the sources say
- Supportedcites [18] 18. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 2022; 28: 2083-91. 19. Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design. Am Heart J 2020; 229: 61-9. source
The Methods (Procedures; page not provided) describe once-weekly subcutaneous semaglutide 2.4 mg for 104 weeks in addition to behavioral intervention. The Discussion reports a mean 15.2% weight loss at week 104 in adults with overweight or obesity without diabetes. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and the 37.8-percentage-point decrease in the high-sensitivity C-reactive protein level with semaglutide in this trial is similar to that reported with statins. 36”
What the sources say
- Supportedcites [36] 36. Asher J, Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich) 2007; 9: 622-8. source
The “CRP Reductions With Statins” section reports CRP reductions of 29% and 43% with atorvastatin monotherapy, making the citing trial’s 37.8-percentage-point decrease a reasonable comparison. The source notes that reductions vary by statin and regimen; it does not assess semaglutide itself. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Similarly, bariatric surgery, in which reductions in body weight of more than 20% can be achieved, has been associated with fewer cardiovascular events than usual care. 33,34”
What the sources say
- Partly supportedcites [33] 33. Mentias A, Aminian A, Youssef D, et al. Long-term cardiovascular outcomes after bariatric surgery in the Medicare population. J Am Coll Cardiol 2022; 79: 1429-37. sourceExperimental — accuracy not yet measured
The Results report fewer heart-failure hospitalizations, myocardial infarctions, and ischemic strokes after bariatric surgery than in the matched control group; the Discussion describes that group as managed conservatively. The Discussion says surgery induces substantial, sustained weight loss, but our copy does not give the claimed reduction of more than 20% of body weight. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [34] 34. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, reductions in excess abnormal body fat ameliorate the systemic proinflammatory and prothrombotic milieu associated with obesity. 31”
What the sources say
- Partly supportedcites [31] 31. Magkos F, Fraterrigo G, Yoshino J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 2016; 23: 591-601. sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report that 11%–16% weight loss was associated with reduced systemic inflammation, but 5% weight loss did not reduce circulating inflammatory markers. The paper does not report an improvement in a prothrombotic milieu, so it supports only the inflammatory part of the claim and only at the greater weight-loss levels studied. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 75 claims and every source verdict.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and, more recently, in people with obesity without diabetes [4].”
From Effects of GLP ‐1 Receptor Agonists and Dual GIP / GLP ‐1 Receptor Agonists on Inflammatory and Metabolic Biomarkers in Type 2 Diabetes: A Systematic Review and Meta‐Analysis (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People were able to maintain approximately 10% WL over a 4-year period, and the proportion of participants experiencing SAE during the trial was lower in those assigned to semaglutide 2.4 mg compared to placebo (33.4% vs. 36.4%).”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial is the first study providing long-term data on the safety and efficacy of semaglutide 2.4 mg [110].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [110]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SELECT trial demonstrated a 20% reduction in MACE among patients with obesity and established cardiovascular disease [15,85].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The findings of benefit on all cardiovascular outcomes and death due to any cause are consistent with the previous meta-analysis but are expanded in important ways including the demonstration of benefit in a population with chronic kidney disease, as well as people with overweight or obese and cardiovascular disease but without diabetes. 26,27”
From Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
71 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Statistical Models Based on Counting Processes
Andersen, P. K., Borgan, Ø., Gill, R. D., & Keiding, N. (1993) · Springer Series in Statistics · doi:10.1007/978-1-4612-4348-9 · Cited by 2,855
Cited by
Items 1,201–1,300 of 3,116
Binu, A. J., & Kapoor, N. (2024) · Heart International · doi:10.17925/hi.2024.18.1.1 · Cited by 6
Bays, H. E., Varney, C., Alexander, L., Ng, J., Tondt, J., Weber, C., Christensen, S. M., Burridge, K., Brown, C., Bindlish, S., et al. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100283 · Cited by 4
Hansrivijit, P., Tesfaye, H., Wexler, D. J., Abdi, R., Patorno, E., & Paik, J. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020651 · Cited by 5
Interventions for the prevention and management of cardiometabolic multiple long-term conditions
Valabhji, J., Hope, D. C. D., SAYED, N. A. E., Godia, P., Lawson, C. A., Seidu, S., & Khunti, K. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00608-2 · Cited by 6
Oswald, T., Coombs, S., Ellery, S. M., & Liu, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113948 · Cited by 7
Chitsazan, M., Parekh, J. K., Kosyakovsky, L. B., Nemeth, S. M., Lau, E. S., Januzzi, J. L., Wang, T. J., Levy, D. A., Ndumele, C. E., Selvin, E., et al. (2025) · Circulation Heart Failure · doi:10.1161/circheartfailure.125.013112 · Cited by 4
Consensus on glycemic management for patients with coronary heart disease and type 2 diabetes
Ji, L., & Chen, Y. (2024) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2024.07.007 · Cited by 6
Odoardo, L. A. F. D., Zucchetti, O., Sciatti, E., D’Isa, S., D’Elia, E., & Senni, M. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suaf032 · Cited by 6
Jensterle, M., & Janež, A. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2554668 · Cited by 5
Rahmouni, K. (2024) · Hypertension · doi:10.1161/hypertensionaha.124.22066 · Cited by 4
Targeting cardiometabolic risk in type 1 diabetes through incretin physiology
Frampton, R., HOCKING, S. L., SNAITH, J. R., & Greenfield, J. R. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.06.004 · Cited by 4
Obesity and Heart Failure With Reduced Ejection Fraction
Khan, M. S., Javaid, S. S., Petrie, M. C., Zieroth, S. R., Anker, S. D., & Butler, J. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.02.5083 · Cited by 12
The Confusing Landscape of Cardiovascular Health Assessment, Promotion, and Prediction
Everett, B. M. (2024) · Circulation · doi:10.1161/circulationaha.123.067982 · Cited by 4
Hellenkamp, K., Sato, R., & von Haehling, S. (2025) · Med · doi:10.1016/j.medj.2024.12.004 · Cited by 4
Zahid, S., Peng, A. W., Razavi, A. C., Yao, Z., Blumenthal, R. S., & Blaha, M. J. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101281 · Cited by 6
Tachi, K., Agyei-Nkansah, A. A., Atiase, Y., Forkuo, B., & Agyen-Frimpong, V. A. (2026) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2026-002294 · Cited by 10
Singh, S., Kumar, V. C. S., & Aswath, G. (2024) · World Journal of Gastrointestinal Endoscopy · doi:10.4253/wjge.v16.i6.292 · Cited by 7
Oral GLP-1 Receptor Agonists for Weight Loss
Krinsky, D., Marcucci, A., Mullally, J. A., & Frishman, W. H. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000833 · Cited by 4
Ursini, F., Ciaffi, J., & Caporali, R. F. (2025) · RMD Open · doi:10.1136/rmdopen-2025-006025 · Cited by 4
Sazdova, I., Gagov, H., Hadzi‐Petrushev, N., Konaktchieva, M. N., Konakchieva, R., & Mladenov, M. I. (2026) · Applied Sciences · doi:10.3390/app16063027 · Cited by 6
Commentary: Shared decision making for weight‐lowering medications in China
Jia, Q., & Li, S. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.70065 · Cited by 3
Huang, Y., Tsou, M., Li, P., Chen, J., Liu, Y., Meyerowitz‐Katz, G., Tsai, T., & Su, P. (2025) · Advanced Science · doi:10.1002/advs.202518813 · Cited by 8
Hammad, M. A. M., Quesada, S. G., Belczyk, A. L., & Ghoniem, G. M. (2025) · Toxins · doi:10.3390/toxins17110542 · Cited by 8
Alsanea, S., Alkofide, H., Almadi, B., Almohammed, O. A., Alwhaibi, A. M., Alrabiah, Z., & Kalagi, N. A. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.05.009 · Cited by 5
Impact of medical versus surgical weight loss on cardiovascular outcomes
Ostapenko, A., & Ahmed, B. H. (2025) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2025.03.004 · Cited by 5
Kris‐Etherton, P. M., Petersen, K. H., Lamarche, B., Karmally, W., Guyton, J. R., Champagne, C. M., Lichtenstein, A. H., Bray, G. A., Sacks, F. M., & Maki, K. C. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.09.010 · Cited by 5
GLP-1RAs for peripheral artery disease: A remarkable STRIDE in the right direction
Verma, S., & Hess, D. A. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.05.001 · Cited by 5
Galsgaard, K. D., Modvig, I. M., & Holst, J. J. (2025) · Biochemical Society Transactions · doi:10.1042/bst20241062 · Cited by 4
Effect of GLP‐1 Receptor Agonists on Post‐Ablation Atrial Fibrillation Recurrence: A Meta‑Analysis
Shubietah, A. R. M., Elgendy, M. S., Awashra, A., Murad, M. R., Alqudah, M., Gowaily, I., Mohamed, A. A., Emara, A., Olumuyide, E. O., Elbataa, A., et al. (2026) · Pacing and Clinical Electrophysiology · doi:10.1111/pace.70262 · Cited by 6
Singh, K., & Frishman, W. H. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001045 · Cited by 5
Luo, Y., Mu, Y., Chen, W., Wang, H., Zhao, D., Liu, D., Zhang, J., & Ji, L. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16369 · Cited by 4
Time to unshackle the medical treatment of obesity in the NHS
Ansari, S., Mazaheri, T., O'Donnell, K., Waite, M., Cann, A., Abdel-Malek, M., Boyle, L. D., Tweedlie, L., Scholtz, S., Hameed, S., et al. (2024) · Clinical Medicine · doi:10.1016/j.clinme.2024.100206 · Cited by 4
Salvatore, M., Zhang, B., Tang, H., Lu, Y., Zhang, D., Zhou, T., Lu, Y., Amaro, A., Ritchie, M. D., & Chen, Y. (2025) · medRxiv · doi:10.1101/2025.06.03.25328908 · Cited by 4
Barazzoni, R., Monami, M., Buscemi, S., Busetto, L., Luca, M. D., Navarra, G., Ragghianti, B., Silverii, G. A., Belluzzi, A., Mannucci, E., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70204 · Cited by 6
Kamrul-Hasan, A. B. M., Chatterjee, S., Ashraf, H., Nagendra, L., Dutta, D., & Pappachan, J. M. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.11.010 · Cited by 5
Li, W., Liang, X., Sun, N., & Zhang, D. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01948-7 · Cited by 5
Biological and mechanistic pathways of cardiometabolic multiple long-term conditions
Lim, L.-L., Jenkins, A., Prabhakaran, D., Sookoian, S. C., Bannuru, R. R., & Khunti, K. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00607-0 · Cited by 10
Elliott, A. D., Middeldorp, M. E., McMullen, J. R., Fatkin, D., Thomas, L., Gwynne, K. G., Hill, A. P., Shang, C. A., Hsu, M.-P., Vandenberg, J. I., et al. (2024) · Heart Lung and Circulation · doi:10.1016/j.hlc.2024.08.008 · Cited by 6
Sheer drop ahead: reviewing sarcopenia outcomes in elderly patients undergoing bariatric surgery
Stumpf, M. A. M., Cercato, C., de Melo, M. E., & Mancini, M. C. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09946-9 · Cited by 5
Gajos, G. (2024) · Cardiology Journal · doi:10.5603/cj.102158 · Cited by 4
Ameer, F., Villacres, N. Y., Bustos, D., Shah, P., Appah, N., Luzaya, G. N., Corradi, F., Bakare, I. S., Trujillo, J. V., Mylavarapu, M., et al. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01770-x · Cited by 5
“Both the public and medical professionals are interested in GLP-1 and GIP medications due to their potential to reduce the risk of chronic diseases and obesity-related health issues, along with their significant weight-loss benefits [ 73, 74 ].”
Blood Pressure-Lowering Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists
Siddiqi, A. K., Khan, M. S., Kulkarni, A., Hall, M. E., Böhm, M., Díez, J., & Butler, J. (2025) · Current Hypertension Reports · doi:10.1007/s11906-025-01342-7 · Cited by 5
“Notably, major adverse cardiovascular events (MACE), including cardiovascular mortality, MI, and stroke, along with a mean SBP reduction of 3.3 mmHg [63].”
InfluentialDinkla, L., Beavers, K. M., Robbins, R. N., Akpalu, D., Wherry, S. J., Miller, G., Beavers, D. P., Espinoza, S. E., Trejo, J., Stepanenko, A. R., et al. (2025) · Frontiers in Aging · doi:10.3389/fragi.2025.1691007 · Cited by 10
“This trial, which included 40+ months of follow-up, reported an ETD in weight of − 8.5% at 104 weeks (Lincoff et al., 2023) and found nearly a 5-fold higher incidence of hip and pelvic fractures in adults aged 75 years or older using semaglutide compared with placebo (Wegovy FDA, 2019).”
InfluentialRico-Fontalvo, J. E., Reina, M., Soler, M. J., Unigarro-Palacios, M., Castañeda-González, J. P., Quintero, J. J., Raad-Sarabia, M., de Moraes, T. P., & Daza-Arnedo, R. (2024) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2024-0101en · Cited by 7
Lu, Y., Liu, Y., Totojani, T., Kim, C., Khera, R., Xu, H., Brush, J. E., Krumholz, H. M., & Abaluck, J. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.26013 · Cited by 8
Use of Semaglutide (Wegovy) in Adults in France: A Nationwide Drug Utilization Study
Haddy, N., Jourdain, H., Desplas, D., Bertrand, M., Jabagi, M.-J., Rives‐Lange, C., & Zureik, M. (2025) · BioDrugs · doi:10.1007/s40259-024-00699-6 · Cited by 7
Advances in Drug Treatments for Companion Animal Obesity
Zomer, H. D., & Cooke, P. S. (2024) · Biology · doi:10.3390/biology13050335 · Cited by 10
Reinson, T., Bilson, J., Childs, C. E., Buchanan, R. M., Targher, G., & Byrne, C. D. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2025-002038 · Cited by 12
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70167 · Cited by 5
Self-citationBrowne, J., Wu, W., Jiang, L., Bayer, T. A., Kunicki, Z. J., Thompson, M. F., Bozzay, M. L., Vito, A. N. D., Howe, M. D., Singh, M., et al. (2025) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaf143 · Cited by 5
The cardiology community begins to embrace obesity as an important target for cardiovascular health
Sattar, N. A., & Rutter, M. K. (2025) · PLoS Medicine · doi:10.1371/journal.pmed.1004578 · Cited by 4
Semaglutide reduces risk of major cardiovascular events by 20%, finds study
Wise, J. (2023) · BMJ · doi:10.1136/bmj.p2668 · Cited by 4
Tentolouris, A., & Ntanasis‐Stathopoulos, I. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70394 · Cited by 4
“Ideally, they should adopt event-driven designs, similar to SELECT, 1 with prespecified cancer outcomes.”
Achieving equitable access to incretin-based therapies in cardiovascular care
Reddy, T. K., Villavaso, C. D., Pulapaka, A. V., & Ferdinand, K. C. (2024) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2024.100455 · Cited by 11
Srivastava, G., Campbell, S. L., Hill, C. R., Stanley, T. L., Lawson, E. A., Apovian, C. M., Almandoz, J. P., Leggio, L., Lakdawalla, D. N., Dar, M., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.06.015 · Cited by 5
“In the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial [22], a signi fi cant breakthrough in the fi eld of obesity medicine, researchers investigated the effects of semaglutide.”
Access to GLP-1s: Where Do Employers Fit in?
Imboden, M. T. (2025) · American Journal of Health Promotion · doi:10.1177/08901171251335507 · Cited by 4
Mehilli, J., Rudolph, T. K., Waßmann, S., Gaede, L., Borger, M. A., Achenbach, S., Ong, P., Assmann, A., Ghanem, A., Westermann, D., et al. (2025) · Die Kardiologie · doi:10.1007/s12181-025-00755-7 · Cited by 4
Older Adults’ Views on Insurance Coverage for Weight Management Medications
Oshman, L. D., Kirch, M., Solway, E. S., Singer, D., Malani, P., Roberts, J. S., Kullgren, J. T., & Hafez, D. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.2008 · Cited by 7
The Role of GLP-1 Agonists in Mitigating Lorlatinib-Induced Metabolic Syndrome: Two Case Studies
Pietroluongo, E., Pannain, S., Garassino, M. C., & Bestvina, C. M. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.03.002 · Cited by 4
Ambrosy, A. P., Daida, Y. G., Parikh, R., Tan, T. C., Howick, C. K., Alexeeff, S., Lo, J. C.-M., & Go, A. S. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.06.047 · Cited by 5
Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Prevention
Gerstein, H. C., & Sattar, N. A. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.102645 · Cited by 5
Anderson, J. J., Deo, S. V., Welsh, P. I., Mackay, D., Ho, F. K. W., Ferguson, L. D., Celis-Morales, C. A., Gill, J. M. R., Pell, J. P., & Sattar, N. A. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15949 · Cited by 9
Stefanakis, K., de Piñeres, V. G., Veeragandham, P., & Mantzoros, C. S. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156493 · Cited by 6
Semaglutide for Metabolic Dysfunction–Associated Steatohepatitis
Simon, T. G. (2025) · New England Journal of Medicine · doi:10.1056/nejme2504717 · Cited by 7
Anti-inflammatory effects of GLP1-RA drugs
Quintana, L., Tabaza, N., Kurt, B., & Kahles, F. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag218 · Cited by 7
Currie, C., Bjerknes, C., & Framroze, B. (2024) · Marine Drugs · doi:10.3390/md22110490 · Cited by 5
Obesity Alters the Vascular Morphology and VEGF‐A Signaling in Adipose Tissue
Lee, Y., Tukei, K. L., Fang, Y., Kuila, S., Liu, X., & Imoukhuede, P. I. (2025) · FASEB BioAdvances · doi:10.1096/fba.2025-00027 · Cited by 9
Wang, M., Dong, T., Lucero, M., Pan, W., Wang, X., Zhou, L., & Meng, Y. (2025) · Gynecologic Oncology · doi:10.1016/j.ygyno.2025.06.012 · Cited by 6
The prevention of adult cardiovascular disease must begin in childhood: evidence and imperative
Khoury, M., Ware, A. L., & McCrindle, B. W. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01209-z · Cited by 15
Kim, Y. J., Malhi, J. K., Trost, J., Leucker, T. M., Virani, S. S., Newby, L. K., Blumenthal, R. S., & Hariri, E. H. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2024.09.013 · Cited by 5
Gonzalez, F., Reid, M. W., Garcia, J. F., Raymond, J. K., & Chao, L. C. (2025) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2025-0568 · Cited by 5
“The early initiation of GLP-1RA in youth with obesity and type 1 diabetes has the potential to reduce their long-term risk for major adverse cardiovascular events and chronic kidney disease [21, 22].”
Stenberg, E., Cao, Y., Ottosson, J., Hedberg, S., & Näslund, E. B. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15952 · Cited by 6
Galindo, R. J., Lee, C. J., Allen, S. E., Dib, A., Boye, K. S., Thieu, V. T., Dong, W., Sapin, H., & Wiese, R. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16620 · Cited by 3
Glucagon-Like Peptide 1 Receptor Agonists and the Deepening Health Equity Divide in America
Spinelli, K. J., & Oakes, A. H. (2025) · American Journal of Health Promotion · doi:10.1177/08901171251335507b · Cited by 5
Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight lossPreprint
Murugadoss, K., Venkatakrishnan, A., Gregg, C. J., & Soundararajan, V. (2026) · medRxiv · doi:10.64898/2026.04.02.26350077 · Cited by 5
Diretriz de Síndrome Coronariana Crônica – 2025
César, L. A. M., Gowdak, L. H. W., Pavanello, R., Ferreira, J. F. M., Mioto, B. M., Poppi, N. T., Mendonça, C. J. L., Beck, A. L. D. S., de Brito, A. S. X., Abizaid, A., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250619 · Cited by 31
A Systematic Bibliometric Analysis of Cardiovascular Disease Risk in Obesity (2014–2024)
Yang, H., Zhang, T., Wang, D., Loi, E. H., Geng, Q., Wu, B., Wang, X., & Cai, R. (2025) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s504022 · Cited by 6
Advances in the Management of Cardiovascular Disease in the Setting of Human Immunodeficiency Virus
Durstenfeld, M. S., & Hsue, P. Y. (2024) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2024.04.006 · Cited by 3
Larsen, A. T., Melander, S. A., Mohamed, K. E., Petersen, E. A., Benmarce, M., Karsdal, M. A., & Henriksen, K. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118388 · Cited by 3
Florescu, A. G., Pucerea, S. A., Floria, M., Rusu, E., Cuiban, E., Jinga, M., Galrinho, R. D., & Stanciu, S. M. (2025) · Romanian Journal of Military Medicine · doi:10.55453/rjmm.2025.128.6.9 · Cited by 8
Njei, B. M., Al‐Ajlouni, Y. A., Tanih, D. N., Kanmounye, U. S., Boateng, S., Halwani, K. W., Nguefang, G., & Lim, J. K. (2026) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-026-00741-0 · Cited by 4
“…the cardiovascular mortality scenario, semaglutide’s cardioprotective effect was modeled using the hazard ratio for major adverse cardiovascular events reported in the SELECT trial (HR 0.80) [13], which was applied to adjust the probability of cardiovascular death in the semaglutide treatment arm.”
InfluentialWeight loss drugs are effective, but can healthcare systems afford them?
West, S., Koutoukidis, D. A., & Jebb, S. A. (2026) · BMJ · doi:10.1136/bmj.s24 · Cited by 3
Seddio, A. E., Vasudevan, R. S., Jonnalagadda, A., Slevin, J. P., Grauer, J. N., & Fram, B. (2025) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-25-00439 · Cited by 4
Incretin-Based Anti-obesity Medications in Polycystic Ovary Syndrome: The Evidence Map
Jensterle, M., & Janež, A. (2026) · Drugs · doi:10.1007/s40265-026-02325-x · Cited by 5
“Patients who had a medical history of PCOS were included in the STEP Phase 3 clinical development program, but the outcomes in this population were not specifically analyzed in subgroup analysis [38–46].”
Phenotypes of Obesity Hypoventilation Syndrome: Characteristics and Outcomes
Masa, J. F., Ramírez-Molina, V. R., & Calama, C. D. D. (2025) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2591-5583 · Cited by 6
Crispino, S. P., Nusca, A., Ferro, A., Cricco, R., Ciancio, M., Segreti, A., Cavallari, I., Sabatino, M., Potena, L., Ussia, G. P., et al. (2025) · Biomolecules · doi:10.3390/biom15111574 · Cited by 6
GLP-1 Receptor Agonists in Heart Failure With Reduced Ejection Fraction?
Litwin, S. E., Drazner, M. H., & Russo, A. M. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102642 · Cited by 3
Muir, K. C., Stone, C. R., Harris, D. D., Kanuparthy, M., Broadwin, M., Hamze, J., Feng, J., & Sellke, F. W. (2026) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00828.2025 · Cited by 5
How rival weight-loss drugs fare at treating obesity, diabetes and more
Lenharo, M. (2024) · Nature · doi:10.1038/d41586-024-02716-8 · Cited by 4
Khan, S. S., Bhave, N. M., Blumenthal, R. S., Coresh, J., Huang, X., Joseph, J. J., Khera, A., Ho, J. E., Lloyd‐Jones, D. M., Wang, C. C. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001447 · Cited by 19
Karacabeyli, D., & Lacaille, D. V. (2026) · Rheumatology · doi:10.1093/rheumatology/keag147 · Cited by 4
“…pre-existing CV disease, BMI ≥ 27 kg/ m 2 and no diabetes, found that the absolute difference in rate of MACE (i.e. myocardial infarction, stroke or CV death) was 1.5% lower with semaglutide relative to placebo [8.0% vs 6.5%; hazard ratio (HR) of 0.8], yielding a number needed to treat of 67 [16].”
InfluentialSeijas‐Amigo, J., Salgado‐Barreira, Á., Castelo-Dominguez, R., Pérez-Álvarez, M. T., Ponce-Piñón, B., Fernández-Silva, M., Rodríguez-Barreiro, M., Pereira-Pía, M., Iglesias-Moreno, J. M., Gago-García, M., et al. (2025) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2025.103312 · Cited by 5
Akbar, U. A., Mondal, A., Vorla, M., Alruwaili, W., Lacoste, J. L., Thyagaturu, H. S., Shafique, N., Shakeel, S., Taha, A., & Balla, S. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.05.004 · Cited by 3
Walking Further with GLP-1RAs: Lessons from the STRIDE Trial
Pantazopoulos, D., Papachristou, S., Vas, P. R. J., & Παπάνας, Ν. (2025) · The International Journal of Lower Extremity Wounds · doi:10.1177/15347346251385584 · Cited by 4
Global uptake of GLP-1 receptor agonists in obese, non-diabetic patients with cardiovascular disease
Chi, K., Pollanen, S., Hu, J., Lee, P., Mangalesh, S., Ezenna, C. G., Joseph, M., Krishna, M. M., Lin, Y.-S., Acero, L. M. R., et al. (2025) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcaf104 · Cited by 3
Seven unanswered questions about blockbuster weight-loss drugs
May, M. J. (2024) · Nature Medicine · doi:10.1038/s41591-024-03380-1 · Cited by 3
Valério, C. M., Saraiva, J. F. K., Valente, F., van de Sande‐Lee, S., Rocha, V. Z., Rached, F. H., Drager, L. F., Halpern, B., Júnior, W. S. D. S., Trujilho, F. R., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01954-8 · Cited by 11
Murugadoss, K., Varma, G., Venkatakrishnan, A., Gibson, M. C., & Soundararajan, V. (2026) · Biology Methods and Protocols · doi:10.1093/biomethods/bpag020 · Cited by 11
The important role of comorbidities in the management of obesity
Barenbaum, S. R., Tchang, B. G., & Aronne, L. J. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag012 · Cited by 5
Takyi, A. K., Gaffey, R. H., & Shukla, A. P. (2025) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-024-00465-1 · Cited by 4
Metadata
- Authors
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H.
- Affiliations
- Cleveland Clinic (US)
- From the Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland (A.M.L.); Novo Nordisk, Søborg, Denmark (K.B.-F., S.E., S.H.-L., G.K.H., T.K.O., M.M.M., C.W.T.); the Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh (H.M.C.), and the National Institute for Cardiovascular Outcomes Research, University College London, London (J.D.) — both in the United Kingdom; the Department of Biostatistics, University of Washington (S.S.E.), and the Department of Medicine, VA Puget Sound Health Care System and University of Washington (S.E.K.) — both in Seattle; the Department of Vascular Medicine, Academic Medical Center, Amsterdam (G.K.H.); the Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago (R.F.K.); the Department of Internal Medicine (Endocrinology Division) and Peter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-12-14
- Volume
- 389
- Issue
- 24
- Pages
- 2221-2232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4388592674
- Cited by
- 3,236
- References
- 42
- Citations by year
- 2026: 1298 · 2025: 1114 · 2024: 796 · 2023: 25
- FWCI
- 658.51
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, obesity, overweight, cardiovascular outcomes, GLP-1 receptor agonists, pre-existing cardiovascular disease, myocardial infarction, stroke, cardiovascular mortality, adverse events, body mass index, weight loss, SGLT2 inhibitors, SELECT trial, drug safety and efficacy, non-diabetic patients, drug discontinuation, time to first event
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Cardiovascular Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Myocardial Infarction, Obesity, Stroke, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
